Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences 3D-Culture, Organoids & Tox Screening Europe 2019

Daniele Zink's Biography



Daniele Zink, Principal Research Scientist and Team Leader, Institute of Bioengineering and Nanotechology, Agency for Science Technology and Research (A*STAR)

Daniele Zink earned her PhD from the University of Heidelberg, Germany in 1995, and was appointed in 1996 as Research Assistant Professor at the Ludwig-Maximilians University (LMU), Munich, Germany. In 2001 she completed her Habilitation in Cell Biology and was awarded funding of a Junior Group from the Volkswagen-Foundation. She was head of the Junior Group at the LMU until she was appointed in 2007 as Team Leader and Principal Research Scientist by the Institute of Bioengineering and Nanotechnology (IBN) of the Agency for Science, Technology and Research in Singapore. Her research focuses on stem cells and predictive methods for in vitro toxicology/nanotoxicology. This work has been awarded by the US Society of Toxicology and Zink has won the prestigious LUSH Prize (2016, Science Category). Zink is co-founder of the spin-off Cellbae that is specialized on stem cell products and applications, holds 12 patents/patent applications, is Editorial Board Member of Scientific Reports and has > 70 publications, which include publications in Nature, Nature Reviews Cancer, Archives of Toxicology and Nanotoxicology.

Daniele Zink Image

Accurate Prediction of Organ-Specific Toxicities

Friday, 14 June 2019 at 11:00

Add to Calendar ▼2019-06-14 11:00:002019-06-14 12:00:00Europe/LondonAccurate Prediction of Organ-Specific Toxicities3D-Culture, Organoids and Tox Screening Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Predicting toxicity to internal organs with alternative methods is currently a major challenge. We have developed the first methods that predict nephrotoxicity in humans with high accuracy. These methods include a high-throughput platform, which combines high-throughput screening (HTS) with phenotypic profiling and machine learning. With this technology toxicity to renal proximal tubular cells (PTC) could be predicted with 82% or 89% test balanced accuracy, depending on whether primary human PTC or a human PTC line were used. Based on the same technology we have developed a HTS platform for the prediction of hepatotoxicity in humans. This HTS platform has been validated with ~90 compounds that were separated into training and test sets, and both test sensitivity and specificity are in the range of 80%. In addition, we have developed a HTS platform for the prediction of vascular toxicity. Our predictive HTS methods are currently combined with our predictive approaches based on human induced pluripotent stem cells.
 
While the HTS platforms are robust, suitable for rapid compound screening and produce binary (yes/no) results with respect to toxicity prediction, we develop complementary microphysiological systems (MPS) for repeated dose testing. Results obtained with a kidney-specific MPS show a high correlation between IC50 values obtained in vitro and the lowest toxic doses in humans. It is expected that respective MPS can greatly facilitate in vitro to in vivo extrapolations (IVIVE). Current difficulties in this area are one of the major obstacles that prevent applications of in vitro methods in risk assessment.


Add to Calendar ▼2019-06-13 00:00:002019-06-14 00:00:00Europe/London3D-Culture, Organoids and Tox Screening Europe 20193D-Culture, Organoids and Tox Screening Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com